Formulomics™ resolves a complete multi-ingredient formulation against population pharmacogenomic data — across the actionable pharmacogenome — into a single, legible intelligence layer.
Genomic risk has always been read one drug, one gene at a time. Formulomics™ makes the whole formulation the unit of intelligence.
Pharmacogenomic risk is assessed in isolation — a single interaction, evaluated alone. The convergences between ingredients and between genes go unread.
The formulation becomes the unit of analysis — every ingredient, every relevant pharmacogene, and the convergences between them, resolved deterministically and anchored to evidence.
A deterministic, evidence-anchored pipeline — not a black-box prediction engine.
Every ingredient in the formulation enters as a single unit of analysis — not one drug at a time.
Resolved across the actionable pharmacogenome against population genomic data — convergences, not coincidences.
Composite intelligence scores and a structured, defensible, evidence-tiered intelligence report.
Each readout below is taken from a representative analysis of compounded risperidone — real values, mirrored from a Formulomics™ intelligence report.
A single composite score, 0–100, summarizing the formulation's pharmacogenomic risk posture across four tiers.
Where multiple genes converge on one biological vulnerability.
On-target, intra-pathway — exposure-driven D2 ADR convergence.
How a formulation fits a target population, scored across ancestries. DRD2 Taq1A A1 carrier frequency:
The formulation's unique genomic signature and a go / caution verdict. Pathway intensity:
A trial-design enrichment factor for R&D — how much a genomically-informed cohort concentrates signal.
A study enriched for the CYP2D6 × HTR2C stratum reaches power with roughly 71% fewer participants.
Every score resolves into one structured, clinician-ready report — the platform's output.
From molecular initiating event to adverse outcome — demonstrating what can occur and who is predisposed, stated at its true evidence strength. The reference instance: the prolactin axis.
Every risk a formulation carries runs on two clocks: when it became foreseeable from first principles, and when it was proven in the literature. Formulomics Temporal™ reads both — from the molecule's inception to today.
Risperidone's confirmed risk picture was launch-state through 1998, crossed into Moderate at the 2003 review, and completed by 2013. But the predictive frontier ran years ahead: DRD2 (prolactin) led by 8 years, HTR2C (weight gain) by 7 — foreseeable from mechanism half a decade before they were proven. Run every five years, Formulomics holds two records at once: a dated confirmation trail showing each signal was surfaced when proven, and a predictive trail showing which risks were foreseeable earlier — the exact substrate the "knew-or-should-have-known" question turns on.
What was knowable, and when — a diligence trail anchored to evidence milestones, not hindsight.
Separate the proven from the predictable, and put a date on each.
Surface adverse-sequelae axes on the predictive frontier — ahead of confirmation.
Hold a confirmation trail and a predictive trail across the entire lifetime of a formulation.
Considerations, not directives — defensible, evidence-tiered, and ready for the clinic. Proof, not promise: the live output of a representative analysis.
| Metab. | Target | Prolactin | Weight | |
|---|---|---|---|---|
| CYP2D6 | H | M | M | · |
| DRD2 | · | H | H | · |
| HTR2C | · | L | · | H |
| ABCB1 | M | · | M | · |
"Considerations, not directives. Defensible by design."
Formulation-level genomic intelligence on what they compound — the whole preparation read as one unit.
Pharmacogenomic capability framing for products and pipelines — a category-defining intelligence layer.
Population-fit and ingredient-convergence intelligence across every ingredient in the formulation.
Clinician-ready considerations at the point of prescribing — defensible and evidence-tiered.
GES™-driven trial-design enrichment and sample-size efficiency — concentrate signal, shrink cohorts.
Formulomics™ invents and owns the formulation-intelligence category. The list above is where it starts — not where it ends.
Formulomics™ analyzes formulations against population genomic data. It never issues patient-specific directives or predicts an individual outcome — the strength is its honesty.
From CPIC Level A through well-replicated to emerging, each finding is stated at its real evidence tier. Associations are never inflated to causation.
The intelligence is reproducible and traceable to its sources. We show what the platform produces — methodology is disclosed under NDA.
Request access to Formulomics™. Engagements and methodology are disclosed under NDA.